Drugs / PEP-CMV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06639607 | Aug 2026 → Aug 2031 | ependymoma, medulloblastoma | Washington University School of Medicine | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-CMV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06639607 ↗ |
| Modality | Vaccine | “CMV-directed peptide vaccine” NCT06639607 ↗ |
| Route | Other | “Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.” NCT06639607 ↗ |